{"id":182750,"date":"2026-05-12T07:37:14","date_gmt":"2026-05-12T11:37:14","guid":{"rendered":"https:\/\/alphastreet.com\/india\/privi-speciality-chemicals-ltd-priviscl-q4-2026-earnings-call-transcript\/"},"modified":"2026-05-12T07:39:54","modified_gmt":"2026-05-12T11:39:54","slug":"privi-speciality-chemicals-ltd-priviscl-q4-2026-earnings-call-transcript","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/privi-speciality-chemicals-ltd-priviscl-q4-2026-earnings-call-transcript\/","title":{"rendered":"Privi Speciality Chemicals Ltd (PRIVISCL) Q4 2026 Earnings Call Transcript"},"content":{"rendered":"

Note:<\/strong> This is a preliminary transcript and may contain inaccuracies. It will be updated with a final, fully-reviewed version soon.<\/em><\/p>\n

Privi Speciality Chemicals Ltd (NSE: PRIVISCL) Q4 2026 Earnings Call dated May. 12, 2026<\/span><\/strong><\/p>\n

Corporate Participants:<\/h2>\n

Mahesh Babani<\/strong> \u2014 Chairman and Managing Director<\/em><\/p>\n

Sanjeev Patil<\/strong> \u2014 Executive Vice President<\/em><\/p>\n

Narayan Iyer<\/strong> \u2014 Chief Financial Officer<\/em><\/p>\n

Analysts:<\/h2>\n

Unidentified Participant<\/strong><\/p>\n

Rohit Sinha<\/strong> \u2014 Analyst<\/em><\/p>\n

Presentation:<\/h2>\n

Operator<\/strong><\/p>\n

Ladies and gentlemen, good day and welcome to the PV Specialty Chemicals Limited Q4 and FY 2026 earnings conference call. As a reminder, all participant lines will be in the listen only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing Star then zero on the Touchstone phone. From the management we have with us Mr. Mahesh Babhani, Chairman and Managing Director Mr.<\/p>\n

R S Rajan, President Mr. Sanjeev Patil, Executive Vice President, Strategy and Biotechnology Mr. Nara Nair, Chief Financial Officer Ms. Ashwini Shah, Company Secretary and Compliance Officer. Before we begin the conference call, I would like to mention that some of the statements made during the course of today’s call may contain forward looking statements about the company which are based on the beliefs, opinions and expectations of the company as on the date of this call. These statements are not the guarantees of future performance and involve risk and uncertainties that are difficult to predict.<\/p>\n

I now hand the conference over to Mr. Mahesh Babhani, chairman and Managing Director of Preview Specialty Chemicals. Thank you. And over to you sir.<\/p>\n

Mahesh Babani<\/strong> \u2014 Chairman and Managing Director<\/em><\/p>\n

Good evening to everyone and thank you for joining us today. I would take this opportunity to take you beyond our strong FY26 performance. I would like to inform you about Privy’s position today and strength of the foundation that we built for the future. Over the past year we have strategically transformed Privy into a more resilient, diversified and forward looking speciality. Aroma Chemical platform. Today our company is far better positioned than ever before. Supported by our robust diversified portfolio, deep customer relationships, strong R and D and innovation and notable global footprint that allow us to navigate external uncertainty and with confidence.<\/p>\n

With that I hand over my team Rajan Narayan and Sanjeev and Ashwini to answer all the investor questions. Thank you Sanjeev. Thank<\/p>\n

Sanjeev Patil<\/strong> \u2014 Executive Vice President<\/em><\/p>\n

You. This is Sanjeev here. Good evening to all. I believe that you all have had a chance to go through our financial results and investor presentation. I will briefly take you through the operational performance for the quarter ended March 26 and the entire year as well. The industry tailwinds remain firmly intact. Demand for fragrance and flavored ingredients continue to grow driven by rising consumption, paying for premium products and increasing focus on wellness and personal care. In addition, global supply chain are undergoing a structural shift with customers increasingly looking for reliable, high quality and compliant partners, a space where your company privy is strongly positioned operationally, the quarter reflects steady execution across all key priorities.<\/p>\n

We continue to see consistent traction across our core Aroma Chemical portfolio supported by steady demand from global customers. At the same time, our efforts towards increasing contribution from downstream and value added products are progressing well and this is gradually reflected in the overall mix. From a manufacturing standpoint, plant utilizations remain healthy across major product lines. Our teams continue to focus on operational excellence through process optimization, yield improvement, energy efficiency initiatives and debottlenecking programs across the plants.<\/p>\n

These initiatives have helped us improve throughput while maintaining strong cost discipline. On CAPEX front We are on track to complete the first phase of our CapEx expansion by 30 June 2026. Total installed capacity will increase to 54,000 metric ton per annum after this phase of expansion. We are now entering a calibrated ramp up phase and expect these additional capacities to be commissioned progressively over the coming quarters in line with strong demand visibility across key products. In parallel, phase two of our multi specialty Aroma Chemicals project is progressing as planned.<\/p>\n

These investments position us well to drive the next leg of growth with phase and meaningful contribution to both revenues and profitability ahead. The joint venture with Prijeev in quarter four, Prijeev turned the corner and reported profits for the first time. Further, additional capex of rupees 50 crore is being implemented based on the equity infusion by PV and Jivadan in the ratio of 51 and 49%. Going forward, the joint venture will gain further traction on growth and robust profitability. Overall, our focus remains on driving volume growth in core products, improving product mix through higher share of value added products and maintaining cost discipline and operational efficiency.<\/p>\n

As we enter the next phase of growth, we remain focused on disciplined execution, strengthening our product mix and driving operational excellence. We believe this approach will allow us to deliver consistent profitable growth while continuing to create long term value for all our stakeholders. With that I hand over to our CFO Mr. Narayanaiyer<\/p>\n

Narayan Iyer<\/strong> \u2014 Chief Financial Officer<\/em><\/p>\n

For the financial details of the company. Good evening to all and thank you Sanjeev and a warm welcome to all of you. We are pleased to report strong financial performance for the financial year 2526 delivered in a dynamic and evolving macro environment. Our performance reflects strong execution, disciplined cost management and the continued strength of our diversified product portfolio. Our performance for the quarter and the financial year 2526 highlights our ability to protect profitability across cycles and reinforces our confidence in the structural strength of our operations and the organization.<\/p>\n

Let me give you a glimpse on the key highlights for the year 2526 we have reported strong growth despite subdued market a 22% revenue growth on a year on year basis was what we have achieved during 2526. We have delivered 25% plus margins consistently across all quarters and for the financial year 2526 on the EBITDA numbers and we expect to sustain a 20% plus EBITDA margins going forward which is driven by operational efficiencies, improved product mix and increased capacities which is coming over in the next few quarters.<\/p>\n

Our JV with Brigeev is also shaping up very well and we expect meaningful contribution in the coming years. The good news is that Prijeev has earned profits in Q4 on its own and we expect to maintain and improve on the same going forward. Additionally, during the year we continue to make progress on the proposed merger of Triwy Specialty Chemicals Limited, Tri V Fine Sciences Private Limited and Trivee Biotechnologies Private Limited with the parent company. This consolidation is aimed at simplifying the group structure, announcing operational synergies, improving scalability and creating a more integrated platform for future growth.<\/p>\n

We are also pleased to share that the company has recently received an observation letter with no objection from both the stock exchanges, namely BSE and NSE marking an important milestone in the merger process. We shall now go ahead filing with the NCLT the scheme and we expect the approval final coming from NCLT during the financial year 2026-27. Coming now to the financial key highlights, I will touch base on the Quarter four results first and then go to the year at large. During the quarter four the total income achieved by the company was 725.70 crores with a growth of 15.29% on a year.<\/p>\n

On year basis, EBITDA achieved during the set period was 184.41 crores, registering a growth of 25.09% on the previous year. EBITDA margins achieved was 25.41% for the quarter and we expect the company to maintain such similar margins going forward. Profit after tax for the quarter was a strong 95.66 crores as against 63.57 achieved during Quarter 4 of 2425. Coming to the annual numbers for the financial year 2526, the overall income achieved by our company was Rupees 2582.92 crores as against 2121.84 crores achieved last year indicating a growth of 21.73%.<\/p>\n

EBITDA achieved during the year was 665.45 crores as against 474.15 in the previous year indicating an increase of 40.35%. EBITDA margins achieved was 25.76% for the year 2526 as against previous years 22.35%. Profit after tax for the period was 327.54 crores as against 187 crores in the previous year indicating an astounding increase of 75.16% during the year. The total volume of sales achieved was about 42,389 metric tons which indicates an increase of 6.5% over previous year’s volumes achieved.<\/p>\n

My dear friends and shareholders, the overall growth of our company was driven by primarily by volume growth, price increase and an improved product mix. This growth was supported by sustained demand across key end user industries and an increasing traction in our specialty and value added product segments. While input costs remained relatively stable during the year, we continue to focus on operational efficiencies, cost optimization initiatives and improved capacity utilization which supported the margins.<\/p>\n

We have been able to bring down the manufacturing and other administrative expenses which has enabled to improve the EBITDA margins further during the year. Now coming to the balance sheet numbers, As a company we continue to maintain a very prudent capital structure. I am happy to inform that due to the excellent management and constant monitoring and focus, we have been able to bring down our overall working capital cycle to 117 days during the year 2025 26. Our net debt as of March 26 stood at 876 crores.<\/p>\n

This is of course net of cash and surplus money deployed in mutual funds with a net debt to an ebitda ratio of 1.33. Reflecting our focus on maintaining financial flexibility while supporting growth investments, our net debt to equity ratio was a very healthy 0.62 reflecting good generation of profits. As you may have noticed, we continue to improve our ROE and ROCE which during the year we achieved a number of 22.05% and 22.42% respectively, thereby reaffirming our visionary Chairman’s vision that going forward the company’s ROE and ROCE is poised to be in excess of 20%.<\/p>\n

During the year we generated healthy operating cash flows of rupees 550 crores maintaining a comfortable liquidity position. Our Capital Allocation Our focus remains on investing in high return growth opportunities, particularly in expanding our specialty chemicals portfolio, enhancing the backward integration and improving operation efficiency. In line with our commitment to shareholder returns, the Board has recommended a dividend of rupees 10 per share for financial year 2526 with a dividend payout of 100% of the face value of the share, which reflects our confidence in the business outlook and cash flow generation going forward.<\/p>\n

Looking ahead, we remain confident in our ability to deliver sustainable growth. Our strong balance sheet, robust cash flows and disciplined capital allocation strategy position us well to capitalize on emerging opportunities while navigating external uncertainties. With the planned capacity expansion of existing products and the introduction of new specialty products, we have established a clear roadmap and are on track to achieve the vision, the foundation of which was laid by our visionary chairman, Mr.<\/p>\n

Mahesh Babhani of the 5000 crores of revenue and 1000 crore plus in the EBITDA numbers over the next 3 to 4 years, which represents a growth of about 2x. With this I would like to conclude the presentation as of now and open the floor for questions and answers. Thank you. Over to your E Moderator.<\/p>\n

Questions and Answers:<\/h2>\n

Operator<\/strong><\/p>\n

Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question may press Star and one on the Touchstone telephone. If you wish to withdraw yourself from the question queue, you may press Star and two Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles. The first question is from the line of Suman Kumar from Mothilal Oswal. Please go ahead.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Yes, my question regarding gross margin, we have seen a significant dip in gross margin sequentially. Any specific reason for that?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yeah, as you know our business is so structured that 70% of our revenues come from export and most of that are through contracts. So you know in the fourth quarter. And if you see historically also that’s where there is an overlap of, you know, sometimes the raw material contract getting into fourth quarter that is the first quarter for the calendar year and because of this overlap sometimes you have this kind of situation. But as we always say that you should judge PV on an annualized basis and this trend you will find in the last few years.<\/p>\n

Also if you look at the last few years also you will find a similar trend because the way the prices move for the annual contracts for both raw material and finished good, such an overlap and distortion can happen. But that’s only part of the thing and you should look pretty always on annualized basis.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Regarding CAPEX in Q3 FY26 you have given all the timeline of Capex so that CAPEX plan intact or any changes?<\/p>\n

Mahesh Babani<\/strong><\/p>\n

It is intact.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Thank you so much.<\/p>\n

Mahesh Babani<\/strong><\/p>\n

It is intact. We will. We are confident of showing a growth of 20% in the coming year and we are hopeful we’ll also be able to maintain similar EBITDA margins.<\/p>\n

Operator<\/strong><\/p>\n

Does that answer the question? Mr. Simon Kumar.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Hello.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question is from the line of Rohit Sinha from Sunidi Securities. Please go ahead.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Yeah, thank you for taking my question and congratulations for good set of numbers. First question. First question sir. On the, on the Biden side as we are looking at a 20% kind of growth and pretty kind of margin or similar kind of margin. So although we have got the approval of the fine science and other business. So does we take into account this number also on this 20% growth or it would be purely from the existing business only.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Thank you. The numbers are appreciated. The 20% growth that Mr. Mahesh Bhavani talked about is on the standalone basis as it is today. And as and when the scheme of merger happens then of course we’ll be consolidating it.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Got it. Secondly, just wanted to know how we should see the engagement with the MNCs during this tough time of war and how the spot customers behave during the trend and how we are looking at going forward in the coming quarters.<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

So spot customers, you know these are all very delicate questions. You know these calls are recorded so we won’t be able to see but we have a very healthy relationship and very transparent relationship with our customers and they are also able to see that the changes which are happening at these are changes which are, you know, once in a lifetime kind of impact that is there. So there we, because of our transparency and trust, you know, we are able to pass on and it is accepted from our customers<\/p>\n

Mahesh Babani<\/strong><\/p>\n

And I don’t see any reason that we will not be able to pass on the price increase. We are confident that we will be able to pass on the price increase and we, because you see I would yet tell you, I’m not saying I’m the most competitive but I am definitely in the league and people do have confidence by paying 1 or 2% higher. Privy is a better supplier. So we have that confidence that people will pay up. And we do have customer relationships so strong that when we sell a basket, you know, we make sure that the customer has a happy ending and good smile on the face.<\/p>\n

So we do somewhere we have extra margins, we do give something cheaper as a basket. We are keeping our customers happy. That’s our strength. You know, we have 75 products, 15 more in the pipeline, 10 more in the development. Hundred products from one doorstep is a great strength to have<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Great. And on the side as we have invested on under 54 for the capex. So is it towards more towards the revenue improvement or it would be on the margin improvement, I mean anything on the backward integration kind of angle.<\/p>\n

Mahesh Babani<\/strong><\/p>\n

There is no backward integration here. The thing is we are bringing in new additional products and additional revenues.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

So<\/p>\n

Mahesh Babani<\/strong><\/p>\n

In fact this year we expect almost 130 crores of sales instead of 55 last year. And we hope we are working in a bigger direction to see at least in next 3, 4 years we should be at least 300 crores of revenue and with decent margins obviously.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Great. One last question from my side. As our working capital days now stands at around 117 days do we see any increase in this number due to the current situation or it will more or less remain in the similar. Even<\/p>\n

Mahesh Babani<\/strong><\/p>\n

If it increase it won’t be more than 3, 4% because of, you know, we have to be when you increase prices, person make late payments it won’t increase more than 5% or something like that. We are confident be able to manage this situation and we have to. We always want to see a happy customer, a smile on his face keeps our day and keeps our balance sheet very alive.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Got it? Got it sir. That’s it from my side, sir. Thank you and best of luck.<\/p>\n

Mahesh Babani<\/strong><\/p>\n

Thank you. Thank you. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question is from the line of Rohit Nagraj from 361 Capital. Please go ahead.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Thanks for the opportunity and congrats on a very strong set of numbers. The first question is on the raw material sourcing side. So if you could give us a flavor as to how are we protected in terms of inventory, the current sourcing situation and on the entire aggregate raw material basket. What is the kind of cost inflation that we have observed over the last couple of months? Thank you.<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Sure. So there are two categories of raw material we can say one is. One is the renewable raw material for which we have annual contracts. And based on those annual contracts typically we hold about one, one and a half to two months of inventory. And then there is always inventory in transit because most of these are shipped from Europe or from us. So you have another one month of inventory there. So we are covered for almost a quarter for, for regular raw material which are contracted and the other raw materials we are covered for about three months in stock and another two to three months in pipeline.<\/p>\n

So that’s the way we Plan our raw materials and for non pine in based products. Whenever we get into annual contracts that typically six monthly contract, so we keep and maintain visibility for those many months. So that’s the way we function and that’s how we try and mitigate the risk of the volatile situation what we are facing right now.<\/p>\n

Mahesh Babani<\/strong><\/p>\n

So we position our contracts as per the raw materials in hand. We don’t take too many contracts. We reduce our market share with some contracted customers if we see contracts are overburdened. So we maintain a fine balance, we keep our eyes on the wall to maintain the fine balance between customer relationship and sales.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Sure, sir, got that. The second question in terms of the FY26 top line growth of 22%, if you could give us a broader understanding for how much was given through volumes, pricing and the product mix, that is. Thank you,<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Royce. As indicated<\/p>\n

Rohit Sinha<\/strong><\/p>\n

It<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Is about 6.5% on account of volume growth and the balance is on account of the product mix and about 8% odd increase in the prices in fact.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

And just to clarify, was there any material benefit from the forex gains during last year?<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Definitely, because we are a net exporter per se. So there is some amount of forex gain that has happened in 2526. I think what is we are reported is close to about 14 crores or so<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Which<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Falls under other income. Yeah, thank you. Thank<\/p>\n

Rohit Sinha<\/strong><\/p>\n

You. Thank you. Yeah,<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question is from the line of RA from I thought pms. Please go ahead.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Hi, am I audible?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Good, you’re audible. Yes, you<\/p>\n

Operator<\/strong><\/p>\n

Are.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Hello, am I audible?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yeah, but this slide echo in your. Now, now there’s a slide echo in your.<\/p>\n

Operator<\/strong><\/p>\n

Yes, please go ahead. You are audible, sir.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Yeah, thanks for the opportunity. So the question I had was specifically on the new products that they’re going to be coming about which is the ethyl nitol and cyclopentanol. So I wanted to know if the phase two and phase three of CAPEX is taken into consideration specifically for these products or is it, or is the phase two and phase three going to be for the existing products? That will be my first question.<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Okay, shall I answer the first question? Then we’ll come to the second question. Yes, we are working and these projects are already underway. So as you will know, typical projects of this size do take 12 months to 15 months for implementation. So we are at very advanced stage in terms of detail engineering, you know, structural design, equipment design, procurement in for some equipments are started, other equipments we are still in that phase of detailed design. So all the Three products design projects are in full swing.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Right. So sir, could you give some, any timeline as to when these products might be commercialized?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yes. So we are targeting to do by the end of first quarter of next financial year. So by June of next financial year we are targeting to complete this project, mechanical completion as we call it, so that we can start taking the trials and typically in a month’s time after those trials we are in the business of commercial production.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Right. And just to follow up on cyclopentanone specifically like do we have two wait for certain approval periods for this molecule like to some of the clients who we are going to be selling it to. So do we have any approval period for this?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yeah, so we, as we always have been saying that, you know, when we develop a product we do it in the lab and then in the pilot and our lab samples are approved. So customers are aware of this product and they have seen our samples approved. Those, you know, so we are, we are doing that homework simultaneously.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Okay sir, and so the second question was to do the perfural. So where do we see the timeline of this perfural? Backward integration like previous timeline and will this fall in the capex span of phase two and phase three or is that completely separate?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

So this is, this is, we will first establish the finished goods and then we’ll go for backward integration. In the meanwhile we will be, we are trying to get into contracts for buying perfural from outside agencies. If you want me to, you know, talk about the timeline for all it will be post, I would say two years or you know, it’s only after two years that we will get into that particular act.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Okay. So anytime around FY 2829 we can expect for 300. You<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Can expect that project to be that long, right? That’s correct.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

And lastly just one thing on the biotech side which is there’s been mentions of biomass conversion, right? So bio waste into value added products. Could you just talk a bit more on this? Yeah,<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yeah. So we are, we continue to work, this is a very complex technology. So we continue to work on that. And right now we are working on setting up a demonstration plant which has a site which, which has a capacity which is significant. So that demonstration plant is being put up with a capex of around 70 to 75 crore which will then do this thing on few turns per day basis so that we have products coming out of that plant and all the three products will happen simultaneously, energy conversion happen and data will be available.<\/p>\n

So that demonstration plan project is also Underway right now we are, we are at a stage at which we are doing the. We have done the basic engine. We are in the process of doing the detailed engine work for that.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

So this is separate from the E MAL and MAL project, is it?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Oh yes, it is completely separate. Yeah, that’s, that’s good.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Yes. And just on a final note, what could be the end capacity figure? Like let’s say after all these three phases of CAPEX is done.<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Okay,<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Yeah. After all, the first three phases of CapEx expansion, as also mentioned in our investor presentation preview, will have on its own about 72,000 metric tons of capacities.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Right. And the timeline for this, sir,<\/p>\n

Narayan Iyer<\/strong><\/p>\n

It is somewhere around the 28th of June. Optimistically, maybe September 28th. More realistically, I would say that.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Okay, thank you very much, sir.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Thank you. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question is from the line of Rohan Mehta from FICOM family office. Please go ahead.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Hello, sir. Am I audible?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yes,<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Perfect. Thank you so much for the opportunity and congratulations on a good set of numbers. So the 2025 annual report references a lot of molecules including silver, amber, amber, silk, as well as Trivialite and Trivialide. So should we read this as a deliberate shift towards a deeper value chain integration and also structurally higher gross margins going forward? Also, in terms of, I wanted to understand what is the commercialization timing for these products and how do these factor in your FY27 revenue and capacity utilization?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yeah, so I will pass the first part of margins because, you know, obviously you can realize that it is very important for us to, you know, maintain that confidentiality. But these products are already being commissioned right now. One of them is already commission and the other ones will be commissioned during the course of this financial year. I would hesitate to give you margins around that. So you have summarized it well, so that’s where it stands.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Sure. Thank you. And my second question is on raw material and alongside logistics outlook for FY27. So given the recent volatility in crude prices as well as overall energy and fleet cost, could you give some sense of, you know, when it comes to your fuel source? What part of your fuel source is currently crude linked and how are you mitigating that risk? Secondly, when it comes to CST and GTO sourcing, how comfortable are you when it comes to sourcing? And should we think about any margin headwinds from input cost in FY27 or are you comfortable on that front so far,<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

I think we answered this question partially earlier that, you know, 70% of our revenue does come from contracts that we already made and those are in place now. In terms of shipping, you know, time, there could be a delay. I mean to say that there is no delay at all is not correct. But there will be a delay. But that’s about a week or two. And we are well covered for that because we always maintain the stocks which are mentioned in the earlier answer. So we maintain that stock and that’s how, that’s how we try to mitigate the risk of such an event.<\/p>\n

That is max one event like this war. That’s where we stand. And about the raw material pricing and everything. Mr. Bhavani already told you that we are having very good relation with the customers and it’s a very transparent relationship. It built on huge amount of trust. Therefore, you know, wherever it is, it is, you know, it makes a case for us to get a higher price. We do get that.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Sure, sure. Thank you so much for the opportunity and wishing you all the best.<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question is from the line of man from growthspeer Ventures. Please go ahead.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Hi. Hi Sanjeevi. Hi Bhavani. Congratulations for great set of numbers and pleasure to hear from you once again, sir. Actually I have three, four questions. I’ll start with my first. So realizations for us actually tend to be in the range of 560 to 590 rupees per kilogram kind of a region. And as we are seeing that it has increased approximately by 6 to 8% this year. How do we see this moving considering that we have 70% of our revenue as exports and which is actually dollar denominated and hence you will be getting some sort of forex benefit out of it as well and you are moving towards higher value products.<\/p>\n

So how should we model this around and how should we see the quality of business going ahead around the pricing?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

So two things, you know, one is that yes, the, as the as rupee or dollar appreciates against rupee, there would be, there would be slightly higher realization. But you have to always remember when you do the P and L part that our raw materials, also 70% of our raw materials are imported. So to that extent it does get balanced. And also we have some amount of the forex data and all that. So there is obviously a benefit of rupee weakening or rupee depreciation. But it is only, it is only calibrated, you know, it is not something that everything comes to us because we also import raw material.<\/p>\n

So that’s, that’s answering your question about this thing and realization will go up if you see the Trend for the last three years it has been or even five years you can take. It has been steadily going up barring couple of years in between. But it is going up from about 450 rupees to about 525 rupees to 600 rupees in the last financial year. So it is going up and going forward. We have both categories of products. We have majority of the products would be higher value products but cyclopenticon obviously is not a product which is of high value although very good margins.<\/p>\n

But in terms of the pricing it is lower. So you, you will find growth going forward definitely in this number, you know, but it will be calibrated.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

So second question that I have considering the crude oil has gone bonkers and due to that GPO prices have also increased a lot. So for us we have majority of our capacity benchmark to CSC and the price raw material for CSE sort of a waste product that is basically imported from western countries. So considering that our end value is increasing and we have sort of a non linked crude crude raw material of some quantity, do we expect the gross margin which is, which has increased by I think 150 odd basis points this year increase in NAIC stock next to next financial year by any chance?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

No, I think you should consider we always play safe. So we will assume that the gross margin remains at similar level. What we actually do, and that’s what defines privy is that we always look internally and try to improve the efficiencies. So that’s what we have done in the last quarter and we will continue to do that and improve our efficiencies and improve, improve on margins.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Got it, Got it. And so for the new products like Malitol and cyclopentanol, if you can explain to the investors what is the actual benefit to preview for basically making these products because as far as we have known this products are basically imported to India and now there is some CBAM norm is also coming, coming. So could you explain a bit in depth as to what would actually be going on in the industry post and how it’s really differentiated in this new products.<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

So if you really look at it, you know it is strategically similar to what we have been doing so far that is converting the waste into wealth. You know, that’s what, that’s what we define internally. So like we do CST which is a waste into aroma chemicals. Similarly we will be starting with Farfural which is made from waste, that is corn cob and go all the way from making buying corn cob to adding value to make you know, these flavor chemicals and a specialty molecule. So that’s the way we are, we have positioned ourselves, you know, so when we, when we are getting into this vertical which will be ultimately value at up to 1,000 tons in revenue, we are fully packer integrated and we will be the only one of that type.<\/p>\n

And we also have a proprietary technology for making cyclopentamol. So based on this we are differentiated from what others do.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Got it, got it. And this would also be export focused, right? As some as C band norms have come live that would actually help us against our peers.<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yes, yes, you’re right, you’re right.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Got it, got it. And sir, last question for me is if we see standalone margins of PV as an entity, they are actually 27, 28% kind of a range. And as, as in those speech you said that now has also started to become profitable, can we expect the youth total or the console margins to tend towards what standalone entity is quoting at right now? Not exactly 23, 28, but the direction towards it.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Yes, there will definitely be an improvement in the consolidated margins going forward. Now that Prajeev is also, you know, turning itself to a positive.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Got it, got it. That’s it from my congratulations again for great set of numbers and all the very best work. Thank you,<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Thank you,<\/p>\n

Operator<\/strong><\/p>\n

Thank you. Participants who wishes to ask a question may press star and one. Now the next question is from the line of Pratik Srivastava from Nivesh Wisdom. Please go ahead.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Yeah, hello sir, first of all again, congratulations on a great set of numbers. I just have a little more follow up on the raw material, especially on the gum turpentine. So at least from what I know that you know, China is the global dominant supplier with around 60 to 70% of world gum time. So is that also our supplier for gto?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

No.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

All right, so we have derived our pipeline from. That’s right,<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yeah.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

And when we say China plus one, do we have any like new customer who has moved away from Chinese suppliers to us?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

So you know, you see Mr. Babani’s interview in the morning on CNBC. So he actually has, you know really nicely stated that we were born out of China plus one. It is now fashionable to say China plus one. But the necessity of having an alternate supplier for aroma chemicals arose many decades back and that’s how PV came into being. And in terms of acquiring new customers as it is, I think all the FNF companies as well as majority of FMCG companies which buy aroma chemicals, we are supplier to them and they are more than happy to have a source which is in front of Chinese source.<\/p>\n

And even in case where we are seeing China plus one strategy, we never forget about getting back to basics. And I explained in the previous question that we would be fully backward integrated. So that is what gives us the strength. It’s not just that we depend on China plus one, but it also makes ourselves very strong in terms of being fully backward integrated to get into the products that we are getting into.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

To add to what Sanjeev is saying, I’ll literally say that we are indeed China plus one. You know. So on a lighter note, because we are backward integrated, we are definitely China plus plus one.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Great, great, great to hear that. My second question is on this amalgamation of the proposed merger between these, you know, PSL and PDCL into pscl. Any timeline for NCLT approval.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

So as indicated in my opening remarks, we expect that to happen by this financial year. Maybe it can come in the third quarter of this year is what internally we are targeting.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Got it. Thank you. Thank you so much.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question is from the line of mehul Panchwani from 40 cents. Please go ahead.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Thank you so much for the opportunity. And pardon me because I’m new for this company. Sir, are the new specialty products which we are, which are in pipeline and also the bridge expansion. I mean all these will translate into revenues in effort management. All of them. Or I heard that already contributing.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

I<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Think Babani explained in the previous question that in the current financial year Preji will give about 130 or crore of resiliency and against 55 odd. Somewhere in the current financial year. And the other other specialty molecules are still the projects are being implemented and you will find revenues coming from those in the next 18 months or so. From 18 months. Almost<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Right. Thank you so much, sir. And ma’, am, another question is about the margin. The EBITDA margin writings. I heard that sustainable about 25%.<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

That’s correct. And we will endeavor to stay there, you know.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Right. Great. Sir, the last question about the partnership with the multinationals. Can you please share elaborate a little bit on what are we working with these guys.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

That is a JV that we talked about where Mr. Babani also mentioned the numbers. So it is purely manufacturing, certain high ended specialty chemicals exclusively for our JV partner Jivadan essay.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Right. And there are two more, right? Or it’s only<\/p>\n

Narayan Iyer<\/strong><\/p>\n

One. There is only one JV. The other 100 subsidiary of the parent company.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

All right. Okay. Okay, sir. Thank you.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Thank you. Welcome.<\/p>\n

Operator<\/strong><\/p>\n

Thank you. The next question is from the line of Karan Talwar from Dam Capital. Please go ahead.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Yeah, thank you for taking my question and congratulations on a good set of numbers. Just a couple of one from my side. We are seeing that in this quarter. Apparently our other expenses and power together have declined both sequentially as well as YY this past having a strong revenue growth and the prevailing disruption in West Asia, which should have typically increased your freight and logistics cost. So could you please help us understand what has driven this decline?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Yeah. So on the first part, the power part, you know, I will give all the credit to our engineering team who have been working around the clock in terms of saving steam and power, you know, so therefore they for overall fuel cost has come down and we continue to work on that. So we have a program which is called as Promax, wherein we keep on working on utilizing the existing whatever is the residual steam that is left, we try and get value out of that. And that’s how we have brought down the cost of power and steel.<\/p>\n

And going forward you will see this trend continuing. But these improvements come very slow and steady. But certainly. And on the second part of controlling expenses, I think we have HAWK here in our CFO who has been controlling all the cost. And I would leave the list to my end.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Yeah. So there has been a constant monitoring and an endeavor and we have been able to ensure that some of the contracts that we enter into with various CHAs and trade forwarders, the prices have been very, very definitely, concisely and precisely negotiated. And you are able to see the better results out of that. In fact. And our endeavor has always been, as also mentioned by me in my initial speech, that it’s a conscious decision of the entire management effort of bringing down and keeping all the expenses under control.<\/p>\n

And that’s what you would see, that it has helped in improving and increasing the EBITDA margins over the previous years. And we will continue striving for that.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

That’s helpful, sir. Secondly, on the EBITDA side that you mentioned on the current portfolio, now with the current mix, how should we think about the remaining levers for EBITDA expansion from here? What I mean to say is have the benefits of probably product mix optimization from your side stream and the operational efficiencies, have they been largely captured or can we see some meaningful upside from here on as well? This is only<\/p>\n

Narayan Iyer<\/strong><\/p>\n

To answer, you know, so the EBITDA margin should remain at these levels. This is our endeavor. You can’t expect. You know, at the end of the day we. I happened to mention in my earlier thing also that we are manufacturers of chemicals and we are not magicians. So there could be a particular limit up to which we could strive and get the EBITDA margins going up. But with the scale of operations that we are looking at absolute numbers, you will see that it keeps growing around margins. We should be in a position to sustain.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

So would you want to throw some light on if we are in any active discussion with other MNC players like we did with Jivadan? Are there any other in the pipeline as well? Any discussion that you’d like to highlight?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Discussions are always on. But you know, at this stage<\/p>\n

Narayan Iyer<\/strong><\/p>\n

It is too premature for us to say anything. At the appropriate time we will be, you know, bringing the same to the world outside.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

So just ask for mind the state incentive for this year.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Sorry, could you, could you repeat the question?<\/p>\n

Rohit Sinha<\/strong><\/p>\n

What would be the state incentives that we may get from this year?<\/p>\n

Narayan Iyer<\/strong><\/p>\n

So which 25, 26 or 26<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Or 26 as well as for 24.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

See last year around the financials which has been audited on an average we have received about close to 30 odd crores as state incentives from both the Gujarat as well as Maharashtra government. Of course this has been offshoot of a couple of years. Going forward we expect as we have stated that these are incentive schemes basis Maharashtra government and state government of Gujarat mentioning and we should be in a position of getting 50% of the the GST amount on sales made in the state within the local state.<\/p>\n

So we should be in this range only around.<\/p>\n

Rohit Sinha<\/strong><\/p>\n

Thank you so much and organize.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you participants. To ask a question you may press star and 1. The next question is from the line of Sajal Kapoor from anti fragile thinking. Please go ahead.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Yeah, thanks for the opportunity. I have two questions. First, you have spoken about biotechnology, enzymatic chemistry and renewable feedstock as strategic priorities. What I want to understand is the economic crossover point for which product categories or molecules do you believe bio based routes are or can realistically achieve cost parity or cost superiority versus conventional petrochemical synthesis over let’s say next three years. And what are the key bottlenecks still preventing wider commercial adoption today?<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Okay, so I’ll answer this question. So the very purpose of putting a demonstration plan is to assess in detail the overall economics. As we stand here today we do see merits in biotechnology route and adding value to that. So what is it that PV does differently? So majority of work that is going on in Biotechnology right now is about making 2g alcohol or a fuel. Whereas what we are doing is actually a refinery where we have multiple products which are of significantly higher value than alcohol which can at best get you price of 100,507 rupees for a 2g alcohol.<\/p>\n

So we are looking at more higher value products which is what makes these economics plausible. But then having said that, the technology is very complex and that’s why we are putting a demonstration plan which will come up in the next probably 12 months or so. And once we operate that demonstration plan continuously then we will establish the and one of the reasons why these plants do turn out to be economically unviable is the capex cost. So while on operating basis most of the bio waste can is available at through the basis but it is what you do with it in terms of one adding, adding value to it which is what we are doing.<\/p>\n

But on the other hand the capex that is required is significant. So that’s how the return on capital has to be well calibrated which is the reason why you are going for a demonstration plan. So it’s a very cautious approach, cautiously, very optimistic, but cautious. Necessary. That’s the answer your question?<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Yes. What I was trying to get from my question was the economic crossover point because if you see historically new manufacturing paradigms and biotechnology enzymatic chemistry in aroma and fragrances is a new paradigm but they only scale when they start to outperform the incumbents on both the cost as well as the performance. Because you need to achieve both because parity is not superiority as well as at least at par performance or better performance at using a newer sort of manufacturing paradigm.<\/p>\n

So I was just trying to frame my question from that perspective. Are we likely to get there in the next three years or so or is this kind of a more. We<\/p>\n

Sanjeev Patil<\/strong><\/p>\n

Are definitely likely to get there because as I said one of the key parameters there is the what kind of products you are making. So when you make premium products, you know, you definitely make the economics turn in your favor. And that’s what, that’s what we are, we are doing.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

So this, if we get there in three years, this will be a kind of a paradigm shift in the chemicals manufacturing because the whole world, many, many materials are currently they haven’t got any alternate synthesis route other than, you know, the feedstock based on the fossil fuels. And if you could crack biotechnology at scale, keeping the economics and the performance at par, then I think it can be a game changer.<\/p>\n

Mahesh Babani<\/strong><\/p>\n

Yes, indeed it would be for sure. Let me Give you an example. There are two large companies in our space who have succeeded on six or seven products in this space. On six, seven molecules which are large, you know, $30, $40, $50. Now our challenge is coming. When we are doing this, we are confident that about the five molecules we are launching, three of them are below $10 or below $5, but they are one of the items which is few. Percentage of that volume is at $90, $80, $70. But we want to multiply so much that we don’t mind selling it at $50.<\/p>\n

We are having a lot of challenges in assessing the market. So we have been meeting all the customers. In fact, how will the elasticity of demand Spanish out if we launch it at $45? So everyone is confident the market will multiply, multifold if we launch it. So we produce right now only few kilos or maybe 10 kilos. And we are in the process, in the next couple of years, we’ll produce few tons and then take a market research and then launch it. Because we don’t want to put, you know, any shareholder money to this.<\/p>\n

Once we are sure of it, we’ll go full swing and that may take three, four years. So this is beyond 5,000, beyond, beyond 5K stories. And we are working. The top team of Preview is working beyond 5k. 5k, the team is different and beyond 5k the team is different.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

No. Thank you for. Thank. Thanks so much for this comprehensive response. Very sensible thinking. I must appreciate. Look forward to all the execution and in the coming years as well. Thank you so much.<\/p>\n

Mahesh Babani<\/strong><\/p>\n

We surely succeed and it’s our endeavor to do this. We want to bring something good, good molecules on earth so that we will be making a significant name in the world markets. Our expectation is to reach beyond the expectations one can imagine.<\/p>\n

Unidentified Participant<\/strong><\/p>\n

Absolutely amazing to hear that. Thank you so much for all the responses. Thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you, ladies and gentlemen. That was the last question for today. I would now like to hand the conference over to Mr. Nada Nair for closing comments.<\/p>\n

Narayan Iyer<\/strong><\/p>\n

Thank you. On behalf of Previ Specialty Chemicals Ltd. I thank all of your investors, shareholders and every person there attending this call and listening to the perspective from the management of Preview. Thank you everyone and looking forward to keep interacting with all of you going forward. Mr. Mahesh Babani. What is under<\/p>\n

Mahesh Babani<\/strong><\/p>\n

Thank the person who asked that question so that my other shareholders also could listen what we are doing. They’ll also be able to get knowledge of what impossible things we are trying to do. So thank you for that<\/p>\n

Narayan Iyer<\/strong><\/p>\n

On that positive statement and sentence by Mr. Mahesh Babhani, our visionary chairman in Nanjin Delta. We have privy the management team say goodbye as of now. But thank you.<\/p>\n

Operator<\/strong><\/p>\n

Thank you, ladies and gentlemen. On behalf of Previous Specialty Chemicals Ltd. That concludes this conference. Thank you for joining us. And you may now disconnect your lines.<\/p>\n","protected":false},"excerpt":{"rendered":"

Note: This is a preliminary transcript and may contain inaccuracies. It will be updated with a final, fully-reviewed version soon. Privi Speciality Chemicals Ltd (NSE: PRIVISCL) Q4 2026 Earnings Call dated May. 12, 2026 Corporate Participants: Mahesh Babani \u2014 Chairman and Managing Director Sanjeev Patil \u2014 Executive Vice President Narayan Iyer \u2014 Chief Financial Officer […]<\/p>\n","protected":false},"author":2377,"featured_media":147581,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[6349],"tags":[10169,9175,9104,9092,14492,10089],"class_list":["post-182750","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-transcripts","tag-earnings","tag-earnings-call","tag-earnings-conference","tag-earnings-transcripts","tag-financial-results","tag-quarterly-earnings"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/Transcript-thumbnail.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":128954,"url":"https:\/\/alphastreet.com\/india\/privi-speciality-chemicals-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":182750,"position":0},"title":"Privi Speciality Chemicals Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 9, 2022","format":false,"excerpt":"https:\/\/youtu.be\/Jfcmzb7kXAs Key highlights from Privi Speciality Chemicals Ltd (PRIVISCL) Q4 FY22 Earnings Concall Q&A Highlights: Manish Gupta from Solidarity Advisors asked that when PRIVISCL can commercialize its first biotech product. Narayan Iyer CFO said that it expect its experience in the biotech space to give the company a positive output\u2026","rel":"","context":"In "Concall Highlights"","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":170626,"url":"https:\/\/alphastreet.com\/india\/privi-speciality-chemicals-q1-fy26-earnings-results\/","url_meta":{"origin":182750,"position":1},"title":"Privi Speciality Chemicals Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"August 26, 2025","format":false,"excerpt":"Incorporated in 1985, Privi Speciality Chemicals Ltd (Formerly known as Privi Speciality Ltd.) is primarily engaged in the manufacturing, supply and exports of aroma and fragrance chemicals used in soaps, detergents, shampoos, and other fine fragrances. Presenting below are its Q1 FY26 earnings results. \u00a0 Q1 FY26 Earnings Results Consolidated\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Privi Specialty Chemicals Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-18.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-18.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-18.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-18.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-18.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/5-18.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":148069,"url":"https:\/\/alphastreet.com\/india\/privi-speciality-chemicals-ltd-q4fy23-results-out-revenue-grows-by-over-7\/","url_meta":{"origin":182750,"position":2},"title":"Privi Speciality Chemicals Ltd Q4FY23 results out, revenue grows by over 7%","author":"Chirag Gupta","date":"June 2, 2023","format":false,"excerpt":"Incorporated in 1985, Privi Speciality Chemicals Ltd (Formerly known as Privi Speciality Ltd.) is primarily engaged in the manufacturing, supply and exports of aroma and fragrance chemicals used in soaps, detergents, shampoos, and other fine fragrances. Privi Speciality Chemicals Ltd reported Total revenue for Q4 FY23 of \u20b9405 Crore, up\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":142695,"url":"https:\/\/alphastreet.com\/india\/privi-speciality-chemicals-q3fy23-earnings\/","url_meta":{"origin":182750,"position":3},"title":"Privi Speciality Chemicals Q3FY23 Earnings","author":"Karan_Singh","date":"February 23, 2023","format":false,"excerpt":"Privi Speciality Chemicals Ltd (Formerly known as Privi Speciality Ltd.) was started in 1985 and majorly dealt with the exports, supply, and manufacturing of fragrance and aroma chemicals that are used in detergents, soaps, shampoos, and other fine fragrances.\u00a0 Financial Results: In the period ended December 31, 2022, the company\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-482986653.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-482986653.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/01\/iStock-482986653.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":160779,"url":"https:\/\/alphastreet.com\/india\/privi-speciality-chemicals-ltd-q4fy24-18-rise-in-revenue\/","url_meta":{"origin":182750,"position":4},"title":"Privi Speciality Chemicals Ltd Q4FY24; 18% rise in Revenue","author":"Chirag Gupta","date":"May 2, 2024","format":false,"excerpt":"Incorporated in 1985, Privi Speciality Chemicals Ltd (Formerly known as Privi Speciality Ltd.) is primarily engaged in the manufacturing, supply and exports of aroma and fragrance chemicals used in soaps, detergents, shampoos, and other fine fragrances. Financial Results: Privi Speciality Chemicals Ltd reported Revenues for Q4FY24 of \u20b9476.00 Crores up\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-12.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-12.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-12.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-12.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-12.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/05\/image-12.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":156493,"url":"https:\/\/alphastreet.com\/india\/privi-speciality-chemicals-ltd-q2fy24-145-rise-in-profits\/","url_meta":{"origin":182750,"position":5},"title":"Privi Speciality Chemicals Ltd Q2FY24; 145% rise in Profits","author":"Chirag Gupta","date":"November 21, 2023","format":false,"excerpt":"Incorporated in 1985, Privi Speciality Chemicals Ltd (Formerly known as Privi Speciality Ltd.) is primarily engaged in the manufacturing, supply and exports of aroma and fragrance chemicals used in soaps, detergents, shampoos, and other fine fragrances. Financial Results: Privi Speciality Chemicals Ltd reported Revenues for Q2FY24 of \u20b9430.00 Crores up\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-269.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-269.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-269.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-269.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-269.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-269.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/182750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2377"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=182750"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/182750\/revisions"}],"predecessor-version":[{"id":182753,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/182750\/revisions\/182753"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/147581"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=182750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=182750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=182750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}